Micreos - Articles and news items

Eczema wounds diseased by S. aureus contamination

Industry news / 5 August 2016 / Erasmus MC University

A new study has revealed that 70% of eczema patients are colonised with Staphylococcus aureus bacteria (S. aureus, including MRSA) on their skin lesions…

Antibiotics resistance Q&A

Antibiotics resistance Q&A

Issue 3 2016 / 30 June 2016 / Caroline Richards

With the rise in drug-resistant bacterial infections heralding a new, dark era of medicine, antibiotics alternatives could one day become the first-line defence against infectious diseases. With the urgent need to find new approaches clear, Caroline Richards, Editor of European Pharmaceutical Review, interviewed Dr. Bjorn Herpers, Chief Medical Advisor of the Dutch biotechnology firm Micreos, to find out more about the company’s targeted antibacterial products. Micreos is developing a lysin called Staphefekt, which specifically targets Staphylococcus aureus, including meticillin-resistant Staphylococcus aureus (MRSA). Dr. Bjorn also serves as Clinical Microbiologist at Public Health Laboratory, Kennemerland…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...